Research in Your Backyard
In the video featured, learn what thought leaders and experts talked about when they came together to discuss the economic benefits of research and other innovation concepts.
The joint event, hosted by PhRMA and We Work for Health brought together governors, pharma executives, and industry experts to discuss the future of the biotechnology industry in the United States, as well as new innovations that are transforming the way medicine is practiced in the country and around the world.
“ Clinical research in central Massachusetts allows our researchers to be involved in the development of important new medicines for patients. Clinical trials of new medications conducted by biopharmaceutical research companies in collaboration with our research institutions have allowed talented clinicians at facilities in the Worcester area to be engaged in cutting-edge biopharmaceutical science. Treatment trials that target cancer, heart disease and stroke are among the trials being conducted in our area and that has benefited such institutions as the University of Massachusetts Medical School, Reliant Medical Group at Worcester Medical Center and Saint Vincent Hospital" Tim Murray, President and CEO, Worcester Regional Chamber of Commerce
“The nation’s biopharmaceutical research companies are providing a steady source of revenue to local research institutions all over the state at a time when Michigan needs as many boosts to its economy as it can get. The industry, in collaboration with the state’s university medical schools and science centers, local hospitals and contract research organizations, has conducted nearly 3,500 clinical trials of new prescription drugs since 1999. Today, companies and their local partners are conducting nearly 400 trials of new medicines. That’s good news for some chronic disease sufferers who are still seeking the treatments best for them and it is certainly welcome news to Michigan’s research collaborators since clinical trials account for 45 to 75 percent of the $1.2 billion average cost of developing just one new novel treatment.” Stephen Rapundalo, President & CEO, MichBio
“ Advancements in medicine would not be possible without individuals willing to volunteer their time to participate in clinical studies. The Minnesota Clinical Research Association (MCRA) is a collaboration of Minnesota based research institutions and professionals who are committed to objectively informing the general public to the benefits and risks involved in clinical research far beyond international and domestic regulations. MCRA members believe that a fully informed participant is critical to successful clinical research outcomes.” Jeff Cosgrove, President, Prism Clinical Research
“The future of disease treatment depends entirely on the clinical trials process. Their aim is to get faster, better, more effective therapies to patients. As a patient advocate, I know these trials have the potential to mitigate and eventually eradicate the devastating impact of diseases like Alzheimer’s, cancer, and heart disease. Patients and their families can hope to live longer and healthier lives because of research being conducted in Montana and around the world.” Suzanne Belser, Executive Director, Alzheimer’s Association, Montana Chapter
“Clinical trials of new medicines conducted by biopharmaceutical research companies in Nebraska have benefited not only patients, but also the state’s economy. The companies have conducted nearly 2,000 clinical trials in the state since 1999 and by and large, those trials involve collaboration with prominent local research institutions, such as the Fred & Pamela Buffett Cancer Center at the University of Nebraska Medical Center as well as Creighton University School of Medicine and Nebraska Methodist Hospital in Omaha. This research is a revenue source and provides talented Nebraska clinicians the opportunity to work on cutting- edge pharmaceutical development projects that address global healthcare challenges.” Phil Kozera, Executive Director, Bio Nebraska Life Sciences Association
“The biotechnology industry, including biopharmaceutical research and the development of new medicines, is an important and growing part of New York State’s economy. Biopharmaceutical research firms frequently work in partnership with hospitals, medical schools and other research institutions, which facilitates the participation of New Yorkers in thousands of clinical trials throughout the state. Biopharmaceutical research is also a boon to local economies in New York, supporting an estimated 201,000 jobs and generating millions in tax revenues.” Nathan Tinker, Executive Director, New York Biotechnology Association
“The fact that we have top-notch university medical schools, hospitals and specialty treatment centers in the 12-county Piedmont Triad has made our region a center of clinical research. And that distinction should cause more than a few ripples of excitement, considering the resulting beneﬁ ts to patients and the regional economy. Since 1999, institutions like Wake Forest University and Forsyth Medical Center in Winston-Salem, Alamance Regional Cancer Center in Burlington and Moses H. Cone Regional Cancer Center in Greensboro have conducted 2,007 clinical trials of potential new medicines. Over 900 of those trials have targeted our most devastating chronic diseases—heart disease, stroke, cancer, diabetes, mental illnesses and asthma.” Dr. Johnny L. Williams, MD President, Old North State Medical Society
“Though I recognize the positive impact clinical research has on our economy, I am focused more on patients. And it’s important biopharmaceutical companies alone have conducted 500 trials in Southeast North Carolina, with more to come, giving chronic disease sufferers and others who want to participate in trials ample opportunities. For some patients, a trial of a new medicine can be a good therapeutic alternative to discuss with health care providers and clinicians conducting trials. Patients participating in clinical research take an active role in managing their health care, and are contributing to scientific knowledge that could ultimately help treat many other patients.” Kay Castillo, Director of Advocacy, Policy, and Legislation, National Assocation of Social Workers of North Carolina
Biopharmaceutical companies’ close collaboration with clinicians and research institutions in Ohio benefits patients, the state’s economy, and the advancement of sci- ence and patient care. Clinical trial work is good business for the state’s medical schools and clinical research centers and the medicines being tested are often cutting-edge cell and protein treatments with the potential to be safer and more effective than older chemical compound drugs. What’s more, Ohioans contemplating participation in clinical trials, in consultation with their doctors, have a wide range of choices—nearly 500 tests of new medicines for the six most debilitating chronic diseases in America are underway in communities large and small all over the state and they need patient volunteers.
“At Oregon’s only Academic Health Center, OHSU Physicians and Researchers work closely with the Pharmaceutical Industry through Clinical Trials. These studies make cutting edge treatments available to our patients suffering from a wide range of diseases. They also attracted nearly $43 million to Oregon supporting numerous jobs and stimulating the economy.” Oregon Health & Science University